Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

2018228 citationsJournal Articlebronze Open Access

Authors

Solange Peters · University of Lausanne

Rolf A. Stahel · University Hospital of Zurich

Lukas Bubendorf · University Hospital of Basel

Philip Bonomi · Rush University Medical Center

Augusto Villegas · Florida Cancer Specialists & Research Institute

Dariusz M. Kowalski · The Maria Sklodowska-Curie National Research Institute of Oncology

Christina S. Baik

Abstract

T-DM1 showed a signal of activity in patients with HER2-overexpressing (IHC 3+) advanced NSCLC. Additional investigation into HER2 pathway alterations is needed to refine the target population for T-DM1 in NSCLC; however, HER2 IHC as a single parameter was an insufficient predictive biomarker.

Topics & Keywords

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 1, pp. 64-72

DOI: 10.1158/1078-0432.ccr-18-1590

Field-Weighted Citation Impact: 17.63